Is LifeVantage Corp. overvalued or undervalued?

As of 17 October 2025, the valuation grade for LifeVantage Corp. has moved from attractive to very attractive, indicating a stronger outlook for the company. Based on the analysis, LifeVantage appears to be undervalued. The P/E ratio stands at 17, which is significantly lower than the peer Chromadex Corp. at 39.82, while the PEG ratio of 0.11 suggests that the stock is undervalued relative to its growth potential. Additionally, the EV to EBITDA ratio of 8.48 further supports this undervaluation compared to its peers.
In terms of peer comparison, LifeVantage's P/E ratio of 14.81 is favorable when compared to USANA Health Sciences, which has a P/E of 16.23, indicating a better valuation relative to its earnings. Despite recent stock performance showing a decline of 49.74% year-to-date compared to a 13.30% gain in the S&P 500, the long-term perspective is promising, with a 3-year return of 130.63%, outperforming the S&P 500's 81.19% in the same period. This suggests that while the short-term outlook may be challenging, the long-term potential remains strong.